Answers are grounded in this paper and cite their sources.
Review summarizes preclinical mechanisms contributing to hypoxemia in hepatopulmonary syndrome, indicating gaps in treatment.
Hepatopulmonary syndrome (HPS) is a pulmonary vascular disorder of liver disease and portal hypertension, characterized by intrapulmonary vascular dilatations leading to impaired gas exchange and hypoxemia. Liver transplantation currently remains the only effective treatment option with desirable outcomes post‐transplant. The common bile duct ligation model is a rodent model for experimental HPS and has provided valuable insights into the pathophysiological mechanisms contributing to hypoxemia, which mainly include vasodilatation, intrapulmonary angiogenesis and alveolar dysfunction. The complex interactions between the liver, the lungs and the gut, predominantly impacting pulmonary endothelial cells, immune cells and respiratory epithelial cells, producing chemokines, cytokines and angiogenic growth factors underlie the typical alterations in the alveolar microcirculation seen in experimental HPS. Nevertheless, HPS still remains an understudied condition, resulting in limited understanding of the disease and the current lack of treatment options. This review summarizes current preclinical knowledge on the pathophysiological mechanisms driving experimental HPS.
No takes yet. Share an insight, caveat, or question.
Verstraeten et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: